In 2002, Buchang Pharmaceutical was appraised as a national "honest tax paying enterprise" by State Taxation Administration of The People's Republic of China and the All-China Federation of Industry and Commerce. In 2006, the company was awarded "Top Ten Most Growing Enterprises in China Pharmaceutical Industry". In 2007, the company was awarded the title of "People's Relieved Medicine Enterprise", and in August of the same year, it was awarded the "Golden Spectrum Award", the highest annual award in the "China Overall Evaluation List of Pharmaceutical Brands"-the top ten brands of pharmaceutical enterprises in China. In 2008, the company won the honorary titles of "Top 2007 China Commercial Science and Technology 100" and "Top 500 China Private Science and Technology Enterprises in 2008". In March, 2008, the founders of the company, Professor Zhao Buchang and Dr. Zhao Chao, were both elected as deputies to the 11th National People's Congress, which was the highest honor and greatest encouragement given by the Party and the country. In 2009, Professor Zhao Buchang was awarded "60 people in 60 years in the pharmaceutical industry in China", and Mr. Zhao Tao was awarded the "Labor Medal for Enriching People and Prospering Shandong". Dr. Zhao Chao was honored as "Excellent Entrepreneurial Entrepreneur in Shaanxi Province" and "Top Ten Economic Figures in Shaanxi in 2009". The company has always regarded scientific and technological innovation as the main driving force for the enterprise to become bigger and stronger, and paid 960 million yuan in taxes in 20 10, and paid nearly 4 billion yuan in taxes for the country. In 2009, it ranked in the top ten of "Top 100 Pharmaceutical Industries in China" and ranked ninth. 20 10 year 1 1 month, Danhong injection won the "Gold Award for the First Patent of Traditional Chinese Medicine in China"; "Buchang Naoxintong" won the "Top Ten Brand of Traditional Chinese Medicine"; Dr. Zhao Chao was awarded the honorary title of "Economic Person in the Decade of Western Development".
The company has the courage to undertake social responsibilities and has established a good corporate image in the eyes of the public. Since 1997, the company has been among the top taxpayers of local private enterprises for many years. Donations to social welfare undertakings exceeded 300 million yuan. In the Wenchuan earthquake in 2008, the company donated 5 million yuan and won the "Outstanding Contribution Award for Earthquake Relief of Hope Project" by Shaanxi Provincial Committee of Youth League. In June, 2009, sponsored by the company, the Chinese Society of Traditional Chinese Medicine, the Beijing Red Cross Society and some well-known hospitals in the capital jointly launched the "* * * Casting China's Heart–Cardiovascular and Cerebrovascular Health Care Plan in the Western Region" to provide free assistance to patients with cardiovascular and cerebrovascular diseases in poor areas in the west. 20 10 February, the company donated 1 100 million yuan again to promote the sustainable development of the project of "* * * Casting China Heart". In April, the company donated 5 million yuan to Yushu disaster area. "20 10 China Charity Ranking" was selected, ranking second among the "Top Ten Charity Enterprises"; On the "20 10 Hurun Charity List", Professor Zhao Buchang and Zhao Tao and his son were honored as "philanthropists with China characteristics". The company won the "China Medical and Health Industry Social Responsibility Cow Award" for two consecutive years.
Buchang Pharmaceutical will take "modernization of Chinese medicine and internationalization of the market" as its own responsibility, strive to build the first brand of Chinese medicine in China, and constantly contribute to the health of Chinese people!
In the development of more than ten years, the enterprise has always put the political idea of "listening to the Party's words, taking the socialist road, respecting government leaders at all levels, and operating according to the law" in the first place, adhering to the image concept of "professional quality and health messenger", taking "a century-old enterprise" as the development goal, and insisting on "taking the market as the center, being anxious about the market and thinking about what the market thinks" in the operation process, and has formed ". Its unique and advanced corporate culture has become an important force for the rapid development of enterprises.
Since 1997, Buchang Group has been rated as the first taxpayer of private enterprises in Shaanxi Province for many years in a row, with the national tax payment exceeding 1 1 billion. In 20021February, Buchang Group was rated as an "honest tax paying enterprise" by State Taxation Administration of The People's Republic of China and the All-China Federation of Industry and Commerce. In 2006, Buchang Group won the "Top Ten Most Growing Enterprises in China Pharmaceutical Industry". In June 2007, Buchang Group won the honor of "People's Relieved Medicine Enterprise" and Buchang Danhong Injection won the honor of "People's Relieved Medicine". In August, 2007, Buchang Group won the "Golden Spectrum Award", the highest annual award in the overall evaluation list of pharmaceutical brands in China-the top ten brands of pharmaceutical enterprises in China. In 2008, Buchang Group ranked 17 in the list of the top 100 pharmaceutical industries in China. In March 2008, Professor Zhao Buchang, Chairman of Buchang Group, was elected as the representative of the 11th National People's Congress, and Zhao Chao, Chairman of Buchang Pharmaceutical, was elected as the representative of the 11th National People's Congress.
Buchang Group has always attached great importance to scientific research and product development. The Group spends 10% of its sales revenue on scientific research and product development every year, and adheres to the road of independent research and development, with more than 50 kinds of exclusive intellectual property products. The chairman and president have worked out the product development strategies of high, medium, low and long, medium and short for the company. Naoxintong series products and other high-tech products are continuously introduced, such as Buchang Wenxin Granule, Buchang Beitong Danhong Injection and Buchang Delisheng Injection. The business scope covers cardiovascular and cerebrovascular diseases drugs, anti-tumor pure Chinese medicine injections, gynecological drugs, digestive products, generic drugs, western medicines, OTC products, community health education and medical devices. Ten GAP planting bases, strong product reserves, market network and advanced corporate culture constitute the core competitiveness of Buchang. In 2008, Buchang Group won the "Top 2007 China Commercial Science and Technology 100 Enterprise". In June of the same year, Buchang Group won the honorary title of "Top 500 Private Technology Enterprises in China in 2008". Its representative product "Buchang Naoxintong" won the Eureka Gold Award in the 42nd World Invention Expo; The title of "Consumer Trusted Product" issued by China Consumer Protection Foundation; In 2004, it was elected as "the first choice brand for consumers with satisfied product quality in China cardiovascular and cerebrovascular drugs market".
Focusing on the research and development of high-tech new drugs is the general idea of scientific research and development in recent years. For example, biopharmaceuticals, purification technology of traditional Chinese medicine monomers, Parker process technology of drugs and research and development of cephalosporin antibiotic intermediates are all areas involved in the pharmaceutical industry of the Group. The success of these aspects will accelerate the internationalization of step size and stabilize the foundation of the century-old step size industry.
Buchang Group insists on "honesty-based, steady management" and pays attention to product quality, and puts forward that "curative effect is the last word". It strictly follows the national GAP and GMP standards for planting and production, and strictly controls the quality, which has won wide acclaim for the enterprise.